Liquid biopsy startup AOA Dx has collected $17 million to support the development of its diagnostic test for ovarian cancer as well as the platform on which it is based.
The company’s diagnostic platform, GlycoLocate, is designed to detect cell signaling molecules called gangliosides in the blood. Elevated levels are often seen in cancer patients.
AOA Dx Inc was a 2021 MassNextGen awardee. The MLSC’s Massachusetts Next Generation (MassNextGen) Initiative that aims to support a broad network of underrepresented entrepreneurs through funding, coaching, and network building.